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Abstract
 
B7-H1 and B7-DC are ligands for PD-1, a receptor implicated in negative regulation of T and
B cell functions. These ligands, however, also costimulate T cell responses. It remains elusive
whether or not costimulation is mediated through PD-1. By comparative molecular modeling
and site-directed mutagenesis, we found that nonconserved residues between these ligands on
the A
 
 
 
GFCC
 
 
 
C
 
  
 
 face mediate interaction with PD-1. This indicates significant structural het-
erogeneity of the interactions between PD-1 and its ligands. Importantly, ligand mutants with
abolished PD-1 binding capacity could still costimulate proliferation and cytokine production
of T cells from normal and PD-1–deficient mice. Our results reveal unique binding character-
istics of B7-H1 and B7-DC and provide direct evidence for an independent costimulatory re-
ceptor other than PD-1.
Key words: PD-1 ligands • mutagenesis • costimulation • T cell activation
 
Introduction
 
Antigen-specific activation and proliferation of lympho-
cytes are regulated by both positive and negative signals
from costimulatory molecules. The most extensively char-
acterized T cell costimulatory pathway is B7-CD28, in
which B7–1 (CD80) and B7–2 (CD86) can each engage
two receptors, the stimulatory CD28 and the inhibitory
CTLA-4 (CD152). In conjunction with signaling through
the T cell receptor, CD28 ligation increases antigen-spe-
cific proliferation of T cells, enhances production of cyto-
kines, stimulates differentiation and effector function, and
promotes survival of T cells (1–3). In contrast, signaling
through CTLA-4 is thought to deliver a negative signal
that inhibits T cell proliferation, IL-2 production, and cell
cycle progression (4, 5). Recently, new members of the B7
family have been identified, including B7-H1 (6, 7) and
B7-DC (8, 9; both of which are ligands for PD-1), B7-H2
(10–12; a ligand for ICOS), and B7-H3 (13; an as of yet
orphan ligand). Elucidation of functional characteristics of
these ligands is currently the subject of intense studies.
The ligands of B7-CD28 family are expressed on the cell
surface as homodimers with a membrane proximal IgC do-
main and a membrane distal IgV domain, while their re-
ceptors share a common extracellular IgV-like domain.
 
Interactions of receptor–ligand pairs are mediated
predominantly through residues in their IgV domains (14).
In general, IgV domains are described as two-layered
 
 
 
-strands with “front” and “back” sheets (15). The front and
back sheets of CTLA-4 IgV domain consist of strands
 
A
 
 
 
GFCC
 
 
 
 and ABEDC
 
  
 
, respectively (16, 17), whereas the
front and back sheets of the B7 IgV domains are composed
of strands AGFCC
 
 
 
C
 
  
 
 and BED, respectively (18–20).
Crystallographic analysis shows that CTLA-4/B7 binding
interface is dominated by the interaction of the CDR3
analogous loop from CTLA-4, centered on the MYPPPY
motif, with the surface on B7 formed predominately by the
G, F, C, C
 
 
 
, and C
 
  
 
 strands (18, 19). The structure of
CD28 has not yet been determined, however, sequence
homology analysis, mutagenesis studies, and computer
modeling support the idea that the MYPPPY motif is also a
major B7-binding site for CD28 (17, 21). Although the
MYPPPY motif is not conserved in ICOS, our recent
studies have indicated that a related FDPPPF sequence in
the analogous position is also a major determinant for bind-
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ing of ICOS to B7-H2 (22). In addition, crystal structures
of CTLA-4/B7 complexes contain bivalent homodimers of
CTLA-4 with B7-binding sites located distally to the
CTLA-4 dimer interface, which suggests that the CTLA-4
homodimer can bind to noncovalent homodimers of B7–1
or B7–2 to form a lattice of CTLA-4/B7 interactions (18,
19). Formation of such a lattice is thought to trigger the
formation of stable signaling complexes as part of the im-
munological synapse.
B7-H1 (also called PD-L1) and B7-DC (PD-L2) are
new members of the B7 family and share 34% amino acid
identity. Human and mouse orthologs of these ligands
share 70% amino acid identity (7–9, 23). While transcripts
of B7-H1 and B7-DC are found in various tissues (6, 9,
23), the expression profiles of their proteins are quite dis-
tinct. The expression of the B7-H1 protein, although vir-
tually absent in normal tissues except macrophage-like
cells, could be induced in a variety of tissues and cell types
(6, 23, 24). In contrast, expression of B7-DC was only de-
tected on dendritic cells and monocytes (8, 24). It has been
shown that both B7-H1 and B7-DC bind to PD-1 (pro-
grammed cell death-1; references 7–9), a distant member of
the CD28 family with an immunoreceptor tyrosine-based
inhibitory motif (ITIM) in its cytoplasmic domain (25).
PD-1 is expressed on a subset of thymocytes and up-regu-
lated on T, B, and myeloid cells after activation (26). The
phenotypes of PD-1
 
 
 
/
 
 
 
 mice provide direct evidence for
PD-1 being a negative regulator of immune responses in
vivo. In the absence of PD-1, mice on the C57BL/6 back-
ground slowly develop a lupus-like glomerulonephritis and
progressive arthritis (27). PD-1
 
 
 
/
 
 
 
 mice on the BALB/c
background rapidly develop a fatal autoimmune dilated
cardiomyopathy (28). However, substantial evidence indi-
cates that both B7-H1 and B7-DC can function to costim-
ulate T cell responses. In the presence of suboptimal TCR
signals, B7-H1 or B7-DC stimulate increased proliferation
and production of cytokines in vitro (6, 8, 23). Infusion of
B7-H1Ig increases CD4
 
 
 
 T cell responses and T helper
cell–dependent humoral immunity (23). On the other
hand, several in vitro studies indicate a negative regulatory
role for B7-H1 and B7-DC in T cell responses (7, 9).
These seemingly contradictory data could be best inter-
preted by expression of additional receptors on T cells
other than PD-1. Indeed, we have recently shown that B7-
H1 expressed on tumor cells can actively inhibit immune
responses by promoting the apoptosis of effector CTL, and
the apoptotic effect of B7-H1 is mediated largely by recep-
tors other than PD-1 (29).
In this study, we pursued a structure-based approach to
delineate binding sites of B7-H1 and B7-DC for PD-1.
With the aid of three-dimensional models and site-specific
mutagenesis, we have first identified residues that are im-
portant or essential for PD-1 binding and then mapped the
receptor binding sites. Although the location of these bind-
ing sites on the AGFCC
 
 
 
C
 
  
 
 face is similar to the one in
CD80/CD86, residues forming the binding sites are not
conserved in B7-H1/B7-DC, revealing unique receptor
recognition structures. Mutants with impaired PD-1 bind-
 
ing characteristics were still capable of T cell costimulation,
providing sound evidence for the presence of other costim-
ulatory T cell receptors.
 
Materials and Methods
 
Mice and Cell Lines.
 
Female C57BL/6 (B6) mice were pur-
chased from the National Cancer Institute (Frederick, MD). PD-
1–deficient (PD-1
 
 
 
/
 
 
 
) mice were generated as described previ-
ously (30). Mice were used in accordance with NIH guidelines
and under an animal study protocol approved by the Animal Care
and Use Committee of the Mayo Clinic. A stably transfected
Chinese hamster ovary (CHO)
 
*
 
 cell clone secreting fusion pro-
teins was maintained in CHO-S-SFM-II medium (GIBCO
BRL) supplemented with 1% dialyzed FBS (HyClone). Lympho-
cytes and COS cells were grown in DMEM (GIBCO BRL) sup-
plemented with 10% FBS, 25 mM HEPES, 2 mM 
 
l
 
-glutamine, 1
mM sodium pyruvate, 1% MEM nonessential amino acids, 100
U/ml penicillin G, and 100 
 
 
 
g/ml streptomycin sulfate.
 
Ig Fusion Proteins.
 
The fusion proteins containing extracellu-
lar domain of mouse PD-1 linked to mouse IgG2a Fc portion
(PD-1Ig; reference 29) were produced in stably transfected CHO
cells and purified by protein G affinity column as described previ-
ously (22). Total RNA was isolated from mouse spleen cells and
B7-DC cDNA was obtained by reverse-transcription PCR (8).
B7-H1Ig and B7-DCIg were prepared by transiently transfecting
COS cells with plasmid cDNA containing chimeric cDNA of the
extracellular domain of mouse B7-H1 (23) or B7-DC in frame to
the CH2-CH3 portion of human IgG1. The transfected COS
cells were cultured in serum-free DMEM media and concen-
trated supernatants were used as sources for Ig fusion proteins in
the initial binding assay (22). The Ig proteins were further puri-
fied with protein G column for BIAcore analysis and functional
assays as described previously (22).
 
Molecular Modeling.
 
Molecular models of the Ig V-type do-
mains of human B7-H1 (hB7-H1), mouse B7-H1 (mB7-H1), hu-
man B7-DC (hB7-DC), and mouse B7-DC (mB7-DC) were
generated by homology (or comparative) modeling based on
x-ray coordinates of human CD80 and CD86 as seen in the struc-
tures of the CD80/CTLA-4 and CD86/CTLA-4 complexes (18,
19). First, the V-domains of CD80 and CD86 were optimally su-
perimposed and, based on this superposition, sequences of B7
family members were aligned. The superposition and initial align-
ments were performed using the sequence-structure alignment
function of MOE (Molecular Operating Environment; Chemical
Computing Group, Montreal, Quebec, Canada). The alignment
was then manually adjusted to match Ig consensus positions (15)
and map other conserved hydrophobic residues in the target se-
quences to core positions in the x-ray structures. Corresponding
residues in the aligned sequences are thus predicted to have
roughly equivalent spatial positions. This was done because taking
structural information into account is a more reliable alignment
criterion than sequence identity alone, if the primary identity is
low, as in this case. In the aligned region, the average identity of
the compared B7 sequences relative to the two structural tem-
plates, CD80 and CD86, is only 
 
 
 
16%. The final version of the
structure-oriented sequence alignment, which provided the basis
for model building, is shown in Fig. 1 a. Following this align-
ment, core regions of the four models were assembled with MOE
from the structural templates; insertions and deletions in loop re-
 
*
 
Abbreviation used in this paper:
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gions were modeled by applying a segment matching procedure
(31, 32). Side chain replacements were performed using preferred
rotamer conformations seen in high-resolution protein databank
structures (33, 34). In each case, 20 intermediate models were
generated, average coordinates were calculated, and the resulting
structures were energy minimized using a protein force field (35)
until intramolecular contacts and stereochemistry of each model
were reasonable. Graphical analysis of the models, including cal-
culation of solvent-accessible surfaces (36), and residue mapping
studies were performed with InsightII (Accelrys). Color figures
were also generated with InsightII.
 
Site-directed Mutagenesis.
 
All mutants of B7-H1Ig and B7-
DCIg were constructed by two-step PCR where B7-H1Ig and
B7-DCIg cDNA were used as templates, respectively (22). Over-
lapping oligonucleotide primers were synthesized encoding the
desired mutations and two flanking 5
 
 
 
 and 3
 
  
 
primers were de-
signed to contain EcoRI and BglII restriction sites, respectively.
Appropriate regions of cDNA were initially amplified using the
corresponding overlapping and flanking primers. Then, using the
flanking 5
 
 
 
 and 3
 
 
 
 primers, fragments whose sequences over-
lapped were fused together and amplified. PCR products were
digested with EcoRI and BglII and ligated into EcoRI/BglII-
digested pHIg vectors. To verify that the desired mutations were
introduced, each mutant was sequenced using an ABI Prism 310
Genetic Analyzer. Plasmids were transfected into COS cells and
serum-free supernatants were harvested and used as sources for in
vitro binding assays or purified by protein G column for BIAcore
analysis and functional assays.
 
ELISA.
 
Sandwich ELISA specific for B7-H1Ig and B7-
DCIg was established as described previously (22). Briefly, micro-
titer plates were coated with 2 
 
 
 
g/ml goat anti–human IgG
(Sigma-Aldrich) overnight at 4
 
 
 
C. Wells were blocked for 1 h
with blocking buffer (10% FBS in PBS), and then washed with
PBS containing 0.05% Tween 20 (PBS-Tween). COS cell cul-
ture supernatants were added and incubated for 2 h at room tem-
perature. Known concentrations of purified B7-H1Ig were also
added to separate wells on each plate for the generation of a stan-
dard curve. After extensive washing, horseradish peroxidase
(HRP)-conjugated goat anti–human IgG (TAGO, Inc.) diluted
at 1:2,000 was added and subsequently developed with TMB
substrate before stopping the reaction by the addition of 0.5 M
H
 
2
 
SO
 
4
 
. Absorbance was measured at wavelengths of 450 nm on a
microtiter plate reader. Concentrations of mutant fusion proteins
were determined by comparison with the linear range of a stan-
dard curve of B7-H1Ig. Data from triplicate wells were deter-
mined and the standard deviations from the mean were 
 
 
 
10%.
Experiments were repeated at least three times. The ability of the
mutants and wild-type of B7-H1Ig and B7-DCIg to bind PD-1
was measured using a capture ELISA assay. Recombinant PD-1Ig
fusion proteins were coated on microtiter plates at 5 
 
 
 
g/ml over-
night at 4
 
 
 
C. The plates were blocked and washed, and then
COS cell culture media was added, followed by incubation for
2 h at room temperature. After extensive washing, HRP-conju-
gated goat anti–human IgG was added, followed by TMB sub-
strate, and absorbance was measured at 450 nm.
 
Flow Cytometry.
 
293 cells were transfected with a PD-1 GFP
vector, which was constructed by fusing GFP in frame to C ter-
minus of mouse PD-1 full-length cDNA. The cells were har-
vested at 24 h after transfection and incubated in flow cytometry
buffer (PBS, 3% FBS, 0.02% NaN
 
3
 
) with an equal amount of fu-
sion proteins in COS cell culture media on ice for 45 min. An
unrelated fusion protein of human Ig was used as negative con-
trol. The cells were washed, further incubated with fluorescein
 
isothiocyanate (PE)-conjugated goat anti–human IgG (BioSource
International), and analyzed on a FACSCaliber™ (Becton Dick-
inson) with CELLQuest™ software (Becton Dickinson). GFP-
positive cells were gated by FL1.
 
Surface Plasmon Resonance Analysis.
 
Affinity of purified wild-
type and mutant B7-H1 and B7-DC proteins were analyzed on a
BIAcore™ 3000 instrument (BIAcore) as described previously
(22) with modifications. All reagents except fusion proteins were
purchased in prefiltered and degassed form from BIAcore. All ex-
periments were performed at 25
 
 
 
C using 0.1 M HEPES, 0.15 M
NaCl (pH 7.4) as running buffer. Briefly, the PD-1Ig was first im-
mobilized on a CM5 sensor chip (BIAcore AB) by amine coupling
according to BIAcore protocol. A flow cell of the CM5 chip was
derivatized through injection of a 1:1 EDC:NHS mixture for 7
min, followed by injection of 20 
 
 
 
g/ml of PD-1Ig at 10 
 
 
 
l/min
diluted in 10 mM sodium acetate (pH 4.5). The PD-1Ig was im-
mobilized at 2,000 RUs. This was followed by blocking the re-
maining activated carboxyl groups with 1 M ethanolamine (pH
8.5). A control flow cell was prepared in a similar fashion as above,
substituting running buffer in place of PD-1Ig. The fusion proteins
were diluted in running buffer in a concentration series starting
from 3.75 
 
 
 
g/ml. The proteins were injected at a flow rate of 20
 
 
 
l/min for 3 min, and then buffer was allowed to flow over the
surface for 5 min for dissociation data. The flow cells were regen-
erated by a single 30 s pulse with10 mM NaOH. Data analysis was
performed using BIAevaluation software package 3.1 (BIAcore).
 
T Cell Proliferation and Cytokine Assays.
 
T cells of wild-type
B6 mice or PD-1
 
 
 
/
 
 
 
 mice were purified by nylon wool columns
(Robbins Scientific Co.) as described previously (10). The enriched
T cells at 3 
 
 
 
 10
 
5
 
 were cultured in flat-bottomed 96-well micro-
plates that were precoated with anti-CD3 mAb (clone 145–2C11;
BD Biosciences) in the presence of 5 
 
 
 
g/ml indicated Ig fusion
proteins. Proliferation of T cells was determined by incorporation
of 1 
 
 
 
Ci/well 
 
3
 
H-TdR during the last 12 h of the 3-d culture. 
 
3
 
H-
TdR incorporation was counted with a MicroBeta Trilux liquid
scintillation counter (Wallac). To detect cytokine, supernatants
were collected at the indicted time points of cultures, and the con-
centrations of IFN-
 
 
 
 were measured by sandwich ELISA follow-
ing the manufacturer’s instructions (BD Biosciences).
 
Results
 
Sequences, Structures, and Molecular Models.
 
The IgV-
domains in CD80 and CD86 share only limited sequence
identity of 
 
 
 
20% but their three-dimensional structures are
very similar, as revealed by independent crystallographic
studies. As many core or Ig superfamily consensus residue
positions seen in CD80/CD86 are also conserved or con-
servatively replaced in other B7 family members, including
B7-H1 and B7-DC (Fig. 1 a), the significant structural sim-
ilarity between CD80 and CD86 can be extended to other
B7 proteins and exploited for model building and mapping
of important residues. Accordingly, we have built molecu-
lar models of the mouse and human B7-H1 and B7-DC
molecules, as shown in Fig. 1 b.
 
Sequence Analysis in Three Dimensions.
 
In the V-regions,
B7-H1 and B7-DC share more sequence identity than av-
erage across the B7 family, 
 
 
 
34%. As both B7-H1 and B7-
DC bind PD-1, residue conservation could be significant
for the formation of the receptor binding site. Therefore,
we have initially used our models to compare the putativeT
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distribution of conserved residues that are exposed on the
protein surface. Fig. 1 b shows a side-by-side comparison
of these molecular models. Significant conservation of sur-
face residues is indeed observed on the IgV BED faces of
B7-H1 and B7-DC, more so in the human than the mouse
proteins. By contrast, the opposite A
 
 
 
GFCC
 
 
 
C
 
  
 
 face does
not display significant residue conservation. This result is
somewhat unexpected because the corresponding
A
 
 
 
GFCC
 
 
 
C
 
  
 
 face of both CD80 and CD86 contains the
CD28/CTLA-4 binding site. These findings raised the
questions whether or not conserved residues on the BED
face of B7-H1 and B7-DC were important for receptor
binding or, alternatively, whether the binding sites con-
tained nonconserved residues.
 
Mutagenesis Analysis of Receptor Binding Sites.
 
With the
aid of our molecular models, we scanned the IgV-domains
of B7-H1 and B7-DC for conserved and nonconserved
residues on both the BED and A
 
 
 
GFCC
 
 
 
C
 
  
 
 faces and sub-
jected them to site-specific mutagenesis. We mutated resi-
dues in the mouse molecules to enable subsequent func-
tional studies of selected mutant proteins. All the mutants
were expressed as human IgG1-tagged fusion proteins.
Figure 1. Molecular models and struc-
tural characteristics of B7-H1 and B7-DC.
(a) Structure-oriented sequence alignment
of B7 molecules. Sequences of the NH2-
terminal IgV domains of human (h) and
mouse (m) B7 family members were aligned
based on a superposition of x-ray structures
of human CD80 and CD86. The alignment
provided the basis for modeling of human
and mouse B7-H1 and B7-DC. Beta strands
seen in the x-ray structures of CD80/86 are
labeled (A -G) and residue positions, which
are most conserved across the B7 family
(e.g., large hydrophobic, charged/polar, or
cysteine residues), are shaded gray. Many of
these residues map to immunoglobulin con-
sensus and protein core positions and are
thus important for structural integrity. Po-
tential N-linked glycosylation sites in these
proteins are boxed. CD86 residues shown
on a yellow background are involved in the
formation of the crystallographic ho-
modimer interface, which is conserved in
CD80, and residues highlighted in red par-
ticipate in CTLA-4 binding in the structure
of the complex with CD86. Residue posi-
tions in mB7-H1 and mB7-DC that are
most important for PD-1 binding, based on
our mutagenesis studies, are shown in ma-
genta. Three residues in mB7-H1, the mu-
tation of which increased the affinity of the
B7-H1/PD-1 interactions, are shown in
white on a magenta background. Residue
numbers are provided for mB7-H1 (black)
and B7-DC (blue). (b) Molecular models
and conserved residues. Our V-domain
models of mB7-H1 (gold), mB7-DC (sil-
ver), hB7-H1 (yellow), and hB7-DC (light
gray) are shown with solvent-accessible sur-
faces and in two equivalent orientations.
The top view focuses on the BED  -sheet
domain surface and the bottom view on the
opposite A GFCC C   surface (related by
180  rotation around the vertical axis). Res-
idues conserved between mB7-H1 and
mB7-DC are colored blue and residues
conserved between hB7-H1 and hB7-DC
are shown in cyan. As can be seen, conser-
vation of residues on the protein surface
(available for receptor binding) is more dis-
tinct on the BED  -sheet surface than the
A GFCC C   face of the domains, in par-
ticular in the human forms.T
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The concentrations of Ig fusion proteins in serum-free
COS cell culture media were determined by sandwich
ELISA using two nonoverlapping anti–human IgG1 mAbs.
The integrity of fusion proteins was confirmed by Western
blotting analysis, in which each Ig fusion protein was
probed with both anti–human Ig and anti-B7-H1 or anti-
B7-DC mAbs. All analyzed fusion proteins appeared to be
single band with the same size between wild-type and mu-
tants (unpublished data). The binding characteristics of
generated mutant proteins were evaluated for binding to
PD-1 by ELISA and flow cytometry analysis. A total of 21
mB7-H1 and 17 mB7-DC mutants were prepared and
tested. The results are summarized in Tables I and II. We
only considered mB7-H1 and mB7-DC residues impli-
cated in ligand–receptor interactions, if their mutation
caused at least a 50% loss of binding by flow cytometry or
at least one order of magnitude loss by ELISA. Mutation of
about half of the selected residues significantly affected
binding to mPD-1. For mB7-H1, these residues were F67,
I115, K124, I126, and K129 and for mB7-DC, were R56,
S67, E71, R101, I105, D111, and K113. All these impor-
tant residues are located in the C
 
 
 
-, C
 
  
 
- and F-, G-strands
of A
 
 
 
GFCC
 
 
 
C
 
  
 
 faces of the domains (Fig. 1 a). Interest-
ingly, mutation of each of three residues in mB7-H1 (E58,
A69, and C113) increased the binding to mPD-1 three- to
fourfold by ELISA. Thus, these positions must at least be
proximal or directly in interface to the receptor-ligand in-
terface and have not only some tolerance for substitution
but also potential optimization of binding interactions.
Residues in mB7-H1 and mB7-DC that, when mutated,
significantly reduce or abolish PD-1 binding are in equiva-
lent regions of the A
 
 
 
GFCC
 
 
 
C
 
  
 
 face of the domains (with
 
Table I.
 
Summary of Amino Acid Substitutions and the Binding 
Characteristics of the Mouse B7-H1 Mutants
 
Substitutions
 
b
 
PD-1 binding
Mutants
 
a
 
Sites
Nucleic
acid(s)
Amino
acid FACS
 
c
 
ELISA
(%)
 
d
 
B7-H1
 
    
 
100
L27A A
 
 
 
 strand TTG→GCC Leu→Ala      100
E31S A  strand GAG→AGC Glu→Ser     50
S34Y B strand AGC→TAC Ser  →Tyr      60
T37Y B strand ACG→TAC Thr→Tyr     5
D49S B/C loop GAC→AGC Asp→Ser      30
Y56S C strand TAC→AGC Tyr→Ser       100
E58S C strand GAA→AGC Glu→Ser       300
E62S C/C  loop GAG→AGC Glu→Ser      50
F67A C  strand TTT→GCC Phe→Ala   /  2
A69F C  strand GCA→TTC Ala→Phe       300
E72S C  strand  GAG→AGC Glu→Ser      60
K75S C  /D loop AAG→AGC Lys→Ser      100
K89S D strand AAG→AGC Lys→Ser      60
A98F E strand GCC→TTC Ala→Phe      40
Q100S E strand CAG→AGC Gln→Ser      100
C113Y F strand TGC→TAC Cys→Tyr       300
I115A F strand ATA→GCC Ile→Ala  /  3
S117Y F strand AGC→TAC Ser→Tyr      100
K124A G strand AAG→AGC Lys→Ser   3
I126A G strand ATC→GCC Ile→Ala   1.4
K129S G strand AAA→AGC Lys→Ser    35
aAmino acids are numbered from the initiation methionine.
bThe nucleotides or amino acids in front of the “→’’ symbol were re-
placed with the corresponding nucleotides or amino acids after the
“→” symbol.
cThe ability of each mutant binding to PD-1 in the flow cytometry as-
say was scored as relative means of fluorescence compared to wild-type
B7-H1Ig and categorized as follows:      ,  120%;     , 80–
120%;    , 50–80%;   , 20–50%;  , 5–20%;  ,  5%.
dSpecific binding activities were determined for each of the indicated
fusion proteins. The concentration of a mutant protein required giving
an arbitrary A450 the same as that found for B7-H1Ig was determined
from the linear region of binding curves. The value was calculated by
the following formula: % wild-type B7-H1Ig binding   100   (1/
A450mutants)/(1/A450B7-H1Ig) and was expressed as a percentage of
specific binding activity of B7-H1Ig. Each value represents the average
of three determinations from each binding curve and the data are repre-
sentative of four experiments.
Table II. Summary of Amino Acid Substitutions and the Binding 
Characteristics of the Mouse B7-DC Mutants
Substitutionsb PD-1 binding
Mutantsa Sites
Nucleic
acids(s)
Amino
acid FACSc
ELISA
(%)d
B7-DC      100
D33S A  strand GAC→AGC D→S      30
S39Y B strand AGC→TAC S→Y      60
E41S B strand GAG→AGC E→S      100
R56S C strand  AGA→TCT R→S    /   5
S58Y C strand AGT→TAC S→Y      170
D65S C  strand GAT→AGC D→S      100
S67Y C strand TCT→TAC S→Y    /   3
E71S C   strand GAA→AGC E→S    /   2
R72S C   strand AGA→AGC R→S      60
K84S D strand AAG→AGC K→S    /     13
H88A E strand CAC→GCC H→A    /     20
R101S F strand  CGT→AGC R→S     7
L103A F strand CTG→GCC L→A     25
I105A F strand ATC→GCC I→A    0.5
D111S G strand GAC→AGC D→S    0.3
K113S G strand AAG→AGC K→S  /   0.1
T116Y G strand ACG→TAC T→Y    /     20
aAmino acids are numbered from the initiation methionine.
bThe nucleotides or amino acids in front of the “→” symbol were re-
placed with the corresponding nucleotides or amino acids after the
“→” symbol.
cSee Table I legend for the definition of binding activity to PD-1.
dSee Table I legend for the calculation of % specific binding activity to
PD-1Ig. Each value represents the average of three determinations from
each binding curve and the data are representative of four experiments. T
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only one exception in each case), although they are often
distant in sequence (Fig. 2 a). By contrast, mutation of
conserved residues on the BED face did not reduce bind-
ing. Thus, residue conservation on the BED face could be
important for other effects such as ligand dimerization or
recognition of other proteins.
The PD-1 binding sites in B7-H1 and B7-DC map to
equivalent sites on the A GFCC C   face. Fig. 2 b shows a
close-up of the predicted binding site regions. As can be
seen, residues whose mutation negatively (or positively) af-
fects PD-1 binding form a coherent surface in both ligands.
The proximity of important residues and some residues not
important for binding suggests that the observed effects are
specific and not a consequence of global structural pertur-
bation, which is further supported by our ability to pro-
duce higher avidity mutants of mB7-H1. Comparison of
important residue positions confirms that the location of
the putative binding sites in mB7-H1 and mB7-DC closely
corresponds to the CD28/CTLA-4 binding sites in CD86
and CD80 (Fig. 2 c).
Surface plasmon resonance analysis of binding of wild-
type and mutant proteins to PD-1 was largely consistent
with the results from flow cytometry and ELISA (Tables I
and II). B7-H1 mutant C113 has a similar or slightly
higher maximal response (Rmax) value than the wild-
type protein, while the mutant I126 shows minimal bind-
ing to mPD-1 (Fig. 3 a). Mutant B7-DC-K113 does not
bind detectably to PD-1 (Fig. 3 b). These data demon-
strate that the wild type B7-H1 and mutant C113 have
greater steady-state affinity for PD-1 than mutant I126,
similar to wild-type B7-DC compared with the mutant
K113. B7-H1 mutant C113, wild-type B7-H1, and B7-
DC all have similar on-rates and off-rates, while only the
mutants I126 and K113 show slower and no detectable
on- and off-rates, respectively.
Costimulatory Function of B7-H1 and B7-DC Mutants.
The costimulatory potential of wild-type B7-H1, B7-DC,
and selected mutants were also tested. Similar to previously
published data, wild-type B7-H1Ig and B7-DCIg increased
proliferation and IFN-  secretion in the presence of anti-
CD3 mAb (Fig. 4, a and b) and this effect could be largely
abrogated by inclusion of specific mAb to mouse B7-H1 or
B7-DC, respectively (unpublished data). In the absence of
anti-CD3, B7-H1Ig and B7-DCIg up to 10  g/ml in solu-
ble or immobilized forms do not stimulate proliferation of
T cells (unpublished data). We chose the mutants F67 and
I126 of B7-H1 and K113 and D111 of B7-DC for further
study because both F67 and I126 have minimal binding to
Figures 2. Mapping of B7-H1
and B7-DC mutants. (a) The models
of mouse B7-H1 and B7-DC are
shown with solvent-accessible sur-
face and in the same orientation as in
b. Residues in mB7-H1 and mB7-
DC that, when mutated, displayed
wild type-like or only partially
( 50%) reduced binding by ELISA
are colored in green. By contrast,
residues whose mutations led to sig-
nificantly ( 50%) reduced or abol-
ished binding by flow cytometry
and/or ELISA are shown in ma-
genta. With one exception in each
case (top), these residues map to
corresponding regions on the
A GFCC C   faces (bottom) of the
domains that are thus predicted to
contain the PD-1 binding sites in
these proteins. Residues in mB7-H1
whose mutation increased binding
to PD-1 are shown in white. Seven
of eight mB7-DC residues impor-
tant for PD-1 binding are not con-
served in mB7-H1, although they
map to similar spatial positions. (b)
Shown is a close-up view of the
A GFCC C   faces, and important
residues in mB7-H1 and mB7-DC
are labeled (black and blue, respec-
tively). (c) Models of mB7-H1
(gold), mB7-DC (silver), and the
x-ray structures of human CD80 (hCD80; light gray) and human CD86 (hCD86; cyan) are shown in equivalent orientations, focusing on the
A GFCC C   faces of their NH2-terminal Ig V-like domains. Residues in mB7-H1 and mB7-DC identified by mutagenesis as important for PD-1 bind-
ing are colored magenta. None of these residues are conserved. Residues in CD80 and CD86 that contact CTLA-4 in their respective crystallographic
complexes are colored in pink (nonconserved) or red (identical or very similar). Whether or not mutation of each of these residues significantly affects
CTLA-4 binding remains to be determined. However, the side-by-side comparison illustrates that the binding sites in these B7 family members map to
corresponding regions, despite markedly different residue compositions (even if the same receptor is recognized).T
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PD-1 in both flow cytometry and ELISA (Table I). Simi-
larly, K113 and D111 do not bind PD-1 (Table II). As
shown in Fig. 4, a and b, these mutants were still able to
costimulate proliferation and IFN-  production of T cells
in comparison with the wild-type of B7-H1 and B7-DC.
In fact, mutants F67 and I126 of B7-H1 had even slightly
increased costimulatory ability compared with wild-type
B7-H1. Mutant D111 of B7-DC appeared to stimulate
lower levels of IFN-g release than wild-type B7-DC in our
assay. This difference, however, was not statistically signifi-
cant (Fig. 4 b). Interestingly, mutant C113, which shows
an approximately threefold better binding capacity in
ELISA to PD-1 than binding of wild-type B7-H1 (Table
I), also costimulated T cell proliferation and IFN-  pro-
duction. Thus, these results suggest that PD-1 is either not
the only costimulatory receptor for B7-H1 and B7-DC or
not a costimulatory receptor at all.
Although B7-H1 and B7-DC might costimulate T cell
growth through a yet unknown receptor, our findings could
be interpreted as an integrated stimulatory effect of uniden-
tified costimulatory receptor(s) and PD-1. Therefore, we
tested costimulatory effects of our mutants in PD-1 deficient
T cells. As shown in Fig. 5, in general, PD-1 /  T cells had
a much higher proliferative potential in response to anti-
CD3 mAb than PD-1 /  T cells (see Fig. 4). Interestingly,
addition of wild-type B7-H1 and its mutants costimulated T
Figure 3. The surface Plasmon resonance analysis of B7-H1 and B7-
DC binding to PD-1. The sensorgram overlay for binding of B7-H1Ig
and its mutants (a) and for binding of B7-DCIg and its mutants (b) to
immobilized PD-1Ig is shown. Flow cell 4 (Fc4) was immobilized with
2000 RU of PD-1Ig. Fc3 was prepared as a control using running buffer.
The response unit is shown for all data, with Fc3 being subtracted from
Fc4. Data was obtained by immobilizing a CM5 sensor chip with 2000
RU of PD-1Ig and by running a concentration series of analyte over the
sensor surface starting at a concentration of 3.75  g/ml up to 60  g/ml.
Figure 4. T cell costimulatory effect of wild-type and mutants of B7-
H1 and B7-DC. (a) Purified T cells from B6 mice were stimulated with
immobilized wild-type or mutants of B7-H1 and B7-DC Ig fusion pro-
teins at 5  g/ml in the presence anti-CD3 mAb at indicated concentra-
tions. Human Ig was used as negative control. The proliferation of T cells
was determined by incorporation of 1  Ci/well of 3H-TdR during the
last 12 h of the 3-d culture. Data depict one representative experiment of
three. (b) For analysis of IFN-  secretion, purified T cells were cultured
in the presence of precoated anti-CD3 (1  g/ml) and 5  g/ml of immo-
bilized Ig fusion proteins and control human Ig. Supernatants were col-
lected after 48 and 72 h culture and assayed for IFN-  using ELISA. Data
depict one representative experiment of three.
Figure 5. Costimulation of PD-1 /  T cells by B7-H1 and B7-DC
mutants. Purified T cells from PD-1–deficient B6 mice were stimulated
with immobilized wild-type or mutants of B7-H1 (a) and B7-DCIg (b) at
5  g/ml in the presence anti-CD3 mAb at indicated concentrations. Hu-
man Ig (hIg) was used as negative control. The proliferation of T cells was
determined by incorporation of 1  Ci/well of 3H-TdR during the last 12 h
of the 3-d culture. Data depict one representative experiment of three.T
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cell proliferation equally well. Similar results were obtained
using wild type B7-DC and its mutants. Thus, these obser-
vations strongly suggest that B7-H1 and B7-DC costimu-
lates T cell growth through a non-PD-1 receptor.
Discussion
With the aid of comparative molecular model and site-
directed mutagenesis, we have generated a first view of
PD-1 binding sites in the NH2-terminal IgV-type domains
of B7-H1 and B7-DC to PD-1. Our site-specific mutagen-
esis analysis has identified residues important for binding of
B7-H1 and B7-DC to PD-1. On the basis of these studies,
we have generated a preliminary outline of PD-1–binding
sites in these two molecules by mapping mutated residues
according to the binding characteristic of their mutants.
Several lines of evidence indicate that it was indeed possible
to select surface residues for mutagenesis from the models
with a high degree of confidence. First, all mutants were
expressed in sufficient quantities for characterization, ruling
out the presence of grossly mis-folded mutant proteins.
Second, the majority of mutants displayed wild-type–like
or only slightly reduced binding. Third, and most impor-
tantly, costimulatory functions of the mutants with mini-
mal binding to PD-1 remained intact, demonstrating that
they were structurally sound. These observations essentially
exclude the presence of significant structural perturbations,
which would typically result from mutations of residues in
the protein core regions.
By mapping of mutants, we could show that B7-H1
and B7-DC utilize nonconserved residues on their
A GFCC C   face to bind PD-1. By contrast, notable
amino acid conservation on the opposite BED faces was
found to be irrelevant for PD-1 binding. Although the lo-
cation of the PD-1 binding sites in B7-H1/B7-DC corre-
sponds to the CD28/CTLA-4 binding sites in CD80/
CD86, receptor binding residues are considerably more
variable in the case of B7-H1 and B7-DC. Thus, PD-1 in-
teractions with B7-H1 or B7-DC must vary significantly at
the molecular level of detail. Considering the unusual de-
gree of variability among residues important for binding
to the same receptor, interactions between receptor and
ligands should be more permissive to modulation in this
case. This notion is consistent with the ability to generate
mutant proteins with higher affinity than wild-type, as
demonstrated here, at least for mB7-H1.
B7-H1 mutants F67, I126, and B7-DC mutants D111,
K113, did not bind PD-1 but were still able to costimulate
T cell proliferation and cytokine production with or with-
out the expression of PD-1 on T cells. These data are con-
sistent with our previous finding that costimulation of T
cells by B7-H1Ig in the presence of anti-CD3 was not af-
fected by the inclusion of soluble PD-1Ig (29). Therefore,
binding to PD-1 and costimulatory functions of B7-H1
and B7-DC could be separated. These findings support that
B7-H1 and B7-DC bind to additional activating receptor(s)
other than PD-1. This scenario is similar to the B7-CD28
pathway where CD80 and CD86 bind two functionally
distinct receptors, CD28 and CTLA-4. It remains to be de-
termined, however, whether or not B7-H1 and B7-DC
bind the same or different costimulatory receptor. Regard-
less, it is likely, based on our present study, that the B7-H1
and B7-DC binding sites for PD-1 and unknown costimu-
latory receptor(s) are distinct. Otherwise, mutants with
substantially impaired PD-1 binding would be expected to
show reduced costimulatory potential.
The studies including those from our laboratory have
shown that both B7-H1 and B7-DC can provide a positive
costimulatory signal for T cell proliferation and cytokine
production (6, 8, 22). Several studies, however, suggested
that engagement of B7-H1 or B7-DC with PD-1 results in
inhibition of T cell proliferation, reducing cytokine pro-
duction and cell cycle arrest (7, 9). We showed previously
that costimulation by B7-H1Ig in the presence of immobi-
lized anti-CD3 induced increased proliferation of human T
cells in 48–72 h but a rapid decrease of T cell number was
observed when the cultures were extended beyond 72 h
(see supplemental data 1 in reference 29). Inhibition of T
cell responses in such prolonged cultures is largely due to
increased apoptosis. It is likely that PD-1 and additional co-
stimulatory receptor may be expressed with different kinet-
ics and/or on different subpopulations of T cells. If putative
costimulatory receptor is expressed earlier than PD-1, en-
gagement of this receptor with B7-H1 or B7-DC may be
responsible for early T cell proliferation and cytokine pro-
duction. Subsequently expressed receptors including PD-1
may mediate cytokine reduction and T cell apoptosis,
which may lead to inhibited T cell responses. Our mutants
thus may provide tools for further dissection of these ex-
perimental observations.
Our findings have important implications in the regula-
tion of immune responses. For example, mutants with se-
lective binding capacity for costimulatory receptor may be
used to stimulate desired immune responses while avoiding
potential inhibition through PD-1 signaling. On the other
hand, mutants selectively binding to PD-1 but not costim-
ulatory receptor could be useful for delivering negative sig-
naling to down-regulate autoimmunity. Our observations
provide a new possibility for the selective manipulation of
ligand binding events and immune responses for therapy.
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